Last checked at 31 Jul 2023 15:19
31 July 2023
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, has been notified that on 28 July 2023, Global Shares Trustees (UK) Limited and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Susanne Munksted, Jordan Clark, Julie Browne and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.
In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.
Enquiries:
Diaceutics PLC | |
Nick Roberts, Chief Financial Officer | Via Alma PR |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Nick Harland | |
Nick Adams Kate Hanshaw | |
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | diaceutics@almapr.co.uk |
Kieran Breheny | |
Matthew Young Kinvara Verdon |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Susanne Munksted | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Precision Medicine Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
0.96 p | 155 | ||||||
Conditional share award: | |||||||
Price(s) | Volume(s) | ||||||
Nil | 155 | ||||||
e. | Date of the transaction | Share purchase and Conditional share award: 28 July 2023 | |||||
f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Jordan Clark | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Commercial Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
0.96 p | 156 | ||||||
Matched share award: | |||||||
Price(s) | Volume(s) | ||||||
0.96 p | 156 | ||||||
e. | Date of the transaction | Share purchase and Matched Share award: 28 July 2023 | |||||
f. | Place of the transaction | Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Julie Browne | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Operations Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
0.96 p | 156 | ||||||
Matched share award: | |||||||
Price(s) | Volume(s) | ||||||
0.96 p | 156 | ||||||
e. | Date of the transaction | Share purchase and Matched Share award: 28 July 2023 | |||||
f. | Place of the transaction | Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange | |||||
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Nick Roberts | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Finance Officer | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
0.96 p | 156 | ||||||
Matched share award: | |||||||
Price(s) | Volume(s) | ||||||
0.96 p | 156 | ||||||
e. | Date of the transaction | Share purchase and Matched Share award: 28 July 2023 | |||||
f. | Place of the transaction | Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange | |||||